U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997055) titled 'ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma(R), an Ustekinumab Biosimilar' on May 21.
Brief Summary: ROLL'YN-UST is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided, independently of the study and as part of a shared medical decision, to switch them to STEQEYMA(R). The main aim of this study is to the maintenance of clinical remission 12 months after initiation of a biosimilar as well as patient satisfaction 6 and 12 months after initiation of a biosimilar.
...